Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Ayers

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinomaHung Huynh, Van Chanh Ngo, Joseph Fargnoli, et al.
The Journal of Molecular Diagnostics : JMD|July 29, 2005
Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChipsJames Stec, Jing Wang, Kevin Coombes, et al.
Cancer Journal (Sudbury, Mass.)|December 26, 2002
Global gene expression changes during neoadjuvant chemotherapy for human breast cancerThomas A Buchholz, David N Stivers, James Stec, et al.
The Journal of Clinical Investigation|June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Breast cancer molecular subtypes respond differently to preoperative chemotherapyRoman Rouzier, Charles M Perou, W Fraser Symmans, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 2005
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancerRoman Rouzier, Radhika Rajan, Peter Wagner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumorsLajos Pusztai, Mark Ayers, James Stec, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinomaHung Huynh, Van Chanh Ngo, Joseph Fargnoli, et al.
The Journal of Molecular Diagnostics : JMD|July 29, 2005
Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChipsJames Stec, Jing Wang, Kevin Coombes, et al.
Cancer Journal (Sudbury, Mass.)|December 26, 2002
Global gene expression changes during neoadjuvant chemotherapy for human breast cancerThomas A Buchholz, David N Stivers, James Stec, et al.
The Journal of Clinical Investigation|June 27, 2017
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Jared Lunceford, Michael Nebozhyn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Breast cancer molecular subtypes respond differently to preoperative chemotherapyRoman Rouzier, Charles M Perou, W Fraser Symmans, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 2005
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancerRoman Rouzier, Radhika Rajan, Peter Wagner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesRazvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumorsLajos Pusztai, Mark Ayers, James Stec, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinomaRobert I Haddad, Tanguy Y Seiwert, Laura Q M Chow, et al.
Pageof 4